Showing results (1-10 of 12) with videos related to
Sort By:
Pageof 2
Journal of Virological Methods|March 1, 2017
Lyophilized visually readable loop-mediated isothermal reverse transcriptase nucleic acid amplification test for detection Ebola Zaire RNAChristoph Carter, Kevan Akrami, Drew Hall, et al.Journal of the International AIDS Society|December 21, 2019
Estimation of new HIV diagnosis rates among high-risk, PrEP-eligible individuals using HIV surveillance data at the Metropolitan Statistical Area level in the United StatesRobertino Mera, Susan Scheer, Christoph Carter, et al.Lancet (London, England)|March 14, 2025
Pharmacokinetics and safety of once-yearly lenacapavir: a phase 1, open-label studyVamshi Jogiraju, Pallavi Pawar, Jenna Yager, et al.Plos One|February 29, 2020
Lack of an association between clinical INSTI-related body weight gain and direct interference with MC4 receptor (MC4R), a key central regulator of body weightCarrie McMahon, James L Trevaskis, Christoph Carter, et al.Transgender Health|February 5, 2024
Gender Affirming Hormones Do Not Affect the Exposure and Efficacy of F/TDF or F/TAF for HIV Preexposure Prophylaxis: A Subgroup Analysis from the DISCOVER TrialMichelle S Cespedes, Moupali Das, Jenna Yager, et al.JAMA|March 1, 2024
HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender WomenJeanne Marrazzo, Li Tao, Marissa Becker, et al.Plos One|June 3, 2022
Proactive strategies to optimize engagement of Black, Hispanic/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP)Michelle Cespedes, Moupali Das, J Carlo Hojilla, et al.The Lancet. HIV|July 1, 2021
Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trialOnyema Ogbuagu, Peter J Ruane, Daniel Podzamczer, et al.The Lancet. HIV|July 15, 2024
HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomised, controlled, phase 3 trialDavid A Wohl, Christoph D Spinner, Jason Flamm, et al.AIDS (London, England)|April 2, 2019
Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trialsSamir K Gupta, Frank A Post, José R Arribas, et al.Pageof 2